Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin
Using magnetoencephalography, the authors show that spontaneous neural signal diversity (entropy and Lempel–Ziv complexity) increases reliably under psilocybin, ketamine and LSD—most strongly for single-channel (temporal) LZ—and that these changes correlate with reported intensity of the psychedelic experience. This first application of such measures to the psychedelic state suggests that sustained psychedelic phenomenology corresponds to an elevated level of consciousness as indexed by neural signal diversity.
Authors
- Suresh Muthukumaraswamy
- Robin Carhart-Harris
Published
Abstract
What is the level of consciousness of the psychedelic state? Empirically, measures of neural signal diversity such as entropy and Lempel-Ziv (LZ) complexity score higher for wakeful rest than for states with lower conscious level like propofol-induced anesthesia. Here we compute these measures for spontaneous magnetoencephalographic (MEG) signals from humans during altered states of consciousness induced by three psychedelic substances: psilocybin, ketamine and LSD. For all three, we find reliably higher spontaneous signal diversity, even when controlling for spectral changes. This increase is most pronounced for the single-channel LZ complexity measure, and hence for temporal, as opposed to spatial, signal diversity. We also uncover selective correlations between changes in signal diversity and phenomenological reports of the intensity of psychedelic experience. This is the first time that these measures have been applied to the psychedelic state and, crucially, that they have yielded values exceeding those of normal waking consciousness. These findings suggest that the sustained occurrence of psychedelic phenomenology constitutes an elevated level of consciousness - as measured by neural signal diversity.
Research Summary of 'Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin'
Introduction
Understanding how brain dynamics relate to conscious experience remains a central challenge. Earlier work has distinguished conscious level (how conscious one is) from conscious content (what one is conscious of), and empirical measures such as the perturbational complexity index (PCI), Lempel-Ziv complexity and entropy-based metrics have been shown to decrease with diminished conscious level (for example during anaesthesia and deep sleep). By contrast, relatively little is known about how these measures behave during states that alter conscious content without producing global loss of awareness, such as the psychedelic state. Schartner and colleagues set out to test whether spontaneous MEG signal diversity increases during psychedelic states induced by three different compounds—psilocybin, subanaesthetic ketamine and LSD—compared with placebo. The investigators re-analysed previously collected multidimensional MEG recordings using a suite of signal diversity measures (Lempel-Ziv-derived metrics and coalition entropies), controlled for spectral changes using phase-randomised surrogate data, and examined relations between neural measures and retrospective reports of subjective experience. The aim was to determine whether psychedelic phenomenology is accompanied by elevated neural signal diversity relative to normal wakefulness, and whether any changes map onto particular phenomenological dimensions.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typemeta
- Journal
- Compounds
- Topic
- Authors
- APA Citation
Schartner, M. M., Carhart-Harris, R. L., Barrett, A. B., Seth, A. K., & Muthukumaraswamy, S. D. (2017). Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin. Scientific Reports, 7(1). https://doi.org/10.1038/srep46421
References (9)
Papers cited by this study that are also in Blossom
Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M. et al. · Psychological Medicine (2016)
Lebedev, A. V., Kaelen, M., L€ Ovd En, M. et al. · Human Brain Mapping (2016)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)
Halberstadt, A. L. · Behavioural Brain Research (2014)
Gonza ´lez-Maeso, J., Weisstaub, N. V., Zhou, M. et al. · Neuron (2007)
Kometer, M., Pokorny, T., Seifritz, E. et al. · Psychopharmacology (2015)
Gallimore, A. R. · Frontiers in Human Neuroscience (2015)
Cited By (85)
Papers in Blossom that reference this study
Irrmischer, M., Aqil, M., Luan, L. et al. · Journal of Neuroscience (2025)
Lissemore, J. I., Chaiken, A., Keller, C. J. et al. · Nature Mental Health (2025)
McCulloch, D. E-W., Larsen, K., Johansen, A. et al. · MedRvix (2025)
Singleton, S. P., Timmermann, C., Luppi, A. I. et al. · Communications Biology (2025)
Piccinini, J. I., Perl, Y. S., Pallavicini, C. et al. · Communications Biology (2025)
Stoliker, D., Novelli, L., Khajehnejad, M. et al. · Biorxiv (2025)
Zeifman, R. J., Spriggs, M. J., Kettner, H. et al. · Scientific Reports (2025)
Godfrey, K., Weiss, B., Zhang, X. et al. · Neuroscience Applied (2025)
Lyons, T., Spriggs, M. J., Kerkelä, L. et al. · Biorxiv (2024)
Shinozuka, K., Tewarie, P. K. B., Luppi, A. et al. · Biorxiv (2024)
Show all 85 papersShow fewer
Lewis, E. C., Jaeger, A., Girn, M. et al. · Journal of Psychopharmacology (2024)
Peill, J. M., Marguilho, M., Erritzoe, D. et al. · Journal of Psychopharmacology (2024)
Weiss, B., Leor Roseman, •., Giribaldi, B. et al. · International Journal of Mental Health and Addiction (2024)
Erritzoe, D., Timmermann, C., Godfrey, K. et al. · Nature Mental Health (2024)
Murray, C., Frohlich, J, Haggarty, C. J., Tare, I. et al. · Neuropsychopharmacology (2024)
Mediano, P. A. M., Rosas, F. E., Timmermann, C. et al. · ACS Chemical Neuroscience (2024)
Allen, J., Dames, S., Foldi, C. J. et al. · Molecular Psychiatry (2024)
Rosas, F. E., Mediano, P. A. M., Timmermann, C. et al. · Biorxiv (2023)
McCulloch, D. E-W., Olsen, A. S., Ozenne, B. et al. · MedRvix (2023)
Muthukumaraswamy, S. · Psyarxiv (2023)
Dai, R., Larkin, T. E., Huang, Z. et al. · NeuroImage (2023)
Girn, M., Rosas, F. E., Daws, R. E. et al. · Trends in Cognitive Sciences (2023)
Ort, A., Smallridge, J. W., Sarasso, S. et al. · iScience (2023)
Murphy, N., Tamman, A. J. F., Lijffijt, M. et al. · Neuropsychopharmacology (2023)
Herzog, R., Mediano, P. A. M., Rosas, F. E. et al. · Scientific Reports (2023)
Timmermann, C., Roseman, L., Haridas, S. et al. · PNAS (2023)
Carhart-Harris, R. L., Chandaria, S., Erritzoe, D. E. et al. · Neuropharmacology (2023)
Eckernäs, E., Timmermann, C., Carhart-Harris, R. et al. · Philosophy and the Mind Sciences (2023)
Ruffini, G., Damiani, G., Lozano-Soldevilla, D. et al. · PLOS ONE (2023)
Luppi, A. I., Vohryzek, J., Kringelbach, M. L. et al. · Communications Biology (2023)
Rajpal, H., Mediano, P. A. M., Rosas, F. E. et al. · NeuroImage (2022)
Kwan, A. C., Olson, D. E., Preller, K. H. et al. · Nature Medicine (2022)
Singleton, S. P., Luppi, A. I., Carhart-Harris, R. L. et al. · Nature Communications (2022)
Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)
Cavanna, F., Muller, S., de la Fuente, L. A. et al. · Translational Psychiatry (2022)
Girn, M., Roseman, L., Bernhardt, B. et al. · NeuroImage (2022)
van Elk, M., Yaden, D. B. · Neuroscience and Biobehavioral Reviews (2022)
Luppi, A. I., Hansen, J. Y., Adapa, R. et al. · Biorxiv (2022)
Hipólito, I., Mago, J., Rosas, F. E. et al. · Psyarxiv (2022)
Li, D., Vlisides, P. E., Mashour, G. A. · NeuroImage (2022)
Elman, I., Borsook, D., Pustilink, A. · Neuroscience and Biobehavioral Reviews (2022)
Vollenweider, F. X., Smallridge, J. W. · Pharmacopsychiatry (2022)
Doss, M. K., Madden, M. B., Gaddis, A. et al. · Brain (2021)
Cavanna, F., Muller, S., de la Fuente, L. A. et al. · Translational Psychiatry (2021)
Perry, C. M., Malina, M. · Psychopharmacology (2021)
Zamani, A., Carhart-Harris, R. L., Christoff, K. · Neuropsychopharmacology (2021)
Khan, S. I., Carter, G. T., Aggarwal, S. K. et al. · Frontiers in Neuroscience (2021)
Burt, J. B., Preller, K. H., Demirtaş, M. et al. · eLife (2021)
Kočárová, C., Horacek, J., Carhart-Harris, R. L. · Frontiers in Psychiatry (2021)
Greco, A., Gallitto, G., Rastelli, C. · Entropy (2021)
Savino, A., Nichols, C. D. · Biorxiv (2021)
Teixeira, P. J., Johnson, M. W., Timmermann, C. et al. · Journal of Psychopharmacology (2021)
Jobst, B. M., Atasoy, S., Ponce-Alvarez, A. et al. · NeuroImage (2021)
Pasquini, L., Luke, D., Harris, R. E. et al. · Frontiers in Human Neuroscience (2021)
Pallavicini, C., Cavanna, F., Zamberlan, F. et al. · Journal of Psychopharmacology (2021)
Sanz, C., Pallavicini, C., Carrillo, F. et al. · Consciousness and Cognition (2021)
Kadriu, B., Greenwald, M., Ba et al. · International Journal of Neuropsychopharmacology (2020)
Alamia, A., Timmermann, C., Carhart-Harris, R. L. · eLife (2020)
Varley, T. F., Carhart-Harris, R., Roseman, L. et al. · NeuroImage (2020)
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Girn, M., Mills, C., Roseman, L. et al. · NeuroImage (2020)
Girn, M., Roseman, L., Bernhardt, B. et al. · Biorxiv (2020)
Barnett, L., Muthukumaraswamy, S., Carhart-Harris, R. L. · NeuroImage (2020)
Fuentes, J. J., Fonseca, F., Elices, M. et al. · Frontiers in Psychiatry (2020)
Timmermann, C., Roseman, L., Schartner, M. et al. · Scientific Reports (2019)
Lord, L. D., Expert, P., Atasoy, S. et al. · NeuroImage (2019)
Pallavicini, C., Vilas, M. G., Villarreal, M. et al. · NeuroImage (2019)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)
Scott, G., Carhart-Harris, R. L. · Neuroscience of Consciousness (2019)
Carhart-Harris, R. L. · Current Opinion in Psychiatry (2019)
Timmermann, C., Spriggs, M. J., Kaelen, M. et al. · Neuropharmacology (2018)
Zamberlan, F., Sanz, C., Pallavicini, C. et al. · Frontiers in Integrative Neuroscience (2018)
Bayne, T., Carter, O. · Neuroscience of Consciousness (2018)
Milliere, R., Carhart-Harris, R. L., Roseman, L. et al. · Frontiers in Psychology (2018)
Barrett, F. S., Carbonaro, T. M., Hurwitz, E. et al. · Psychopharmacology (2018)
Schenberg, E. E. · Frontiers in Pharmacology (2018)
Johnson, M. W., Griffiths, R. R., Hendricks, P. S. et al. · Neuropharmacology (2018)
Carhart-Harris, R. L. · Neuropharmacology (2018)
Swanson, L. R. · Frontiers in Pharmacology (2018)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Atasoy, S., Leor, R., Kaelen, M. et al. · Scientific Reports (2017)
Carhart-Harris, R. L., Nutt, D. J. · Journal of Psychopharmacology (2017)
Viol, A., Palhano-Fontes, F., Onias, H. et al. · Scientific Reports (2017)
Elsey, J. W. B. · Drug Science Policy and Law (2017)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.